ANGLE plc's (LON:AGL, OTCQX:ANPCY) ground-breaking liquid biopsy system Parsortix could mean a revolutionary new way of treating breast cancer patients.
The Norris Comprehensive Cancer centre, at the University of Southern California (USC), has been working with the blood test device for the last two years. It has now presented findings showing it could be used to obtain information about potential cancer without the need for an invasive and costly biopsy of tissue.
READ: ANGLE: Vienna study reveals key advantage of company's blood biopsy
Parsortix harvests circulating tumour cells (CTCs) from blood- a tell-tale early sign of the disease.
"Our study showed that we are able to use a Parsortix liquid biopsy of circulating tumor cells to perform in-depth characterization of potentially clinically actionable treatment opportunities in metastatic breast cancer patients," said Dr Julie E. Lang from the USC breast cancer programme.
"Successful validation of our approach in future clinical studies could revolutionize clinical management of metastatic breast cancer and advance the promise of personalised cancer therapies, ultimately positively changing the outcome for patients with metastatic disease."
ANGLE founder Andrew Newland added: "USC's ground-breaking work with ANGLE's Parsortix system over the last two years has delivered convincing data that a simple blood test may be able to provide all the clinical information traditionally provided by the invasive, expensive solid biopsy.
READ: Dutch healthcare and electronics giant Philips to use ANGLE’s Parsortix system as part of four-year collaboration
"This is great news for ANGLE as it gives a clear guide to the importance of being able to harvest and analyse these cells from patient blood."
There is a major market need, says ANGLE, for a blood test alternative which can provide the same or better information non-invasively.
Shares added almost 9% to 51.75p in early deals.